Geovax commences site expansion for phase 2 trial of next-generation covid-19 vaccine

Designed to protect immunocompromised patients against severe covid-19 atlanta, ga, oct. 30, 2023 (globe newswire) -- via newmediawire -- geovax labs, inc. (nasdaq: govx), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it has commenced the planned site expansion for the phase 2 clinical trial investigating its next-generation sars-cov-2 vaccine, geo-cm04s1, as a primary vaccine in immunocompromised patients. in addition to study enrollments completed at the city of hope medical center (duarte, california), the trial will be initiating enrollment of eligible patients at wake forest baptist medical center (winston salem, north carolina), the university of massachusetts medical center (worcester, massachusetts), and fred hutchinson cancer research center (seattle, washington).
GOVX Ratings Summary
GOVX Quant Ranking